|
The global anti-infective market is currently valued at US$66.5 billion with antibacterial agents accounting for over 50% of sales. The antibacterial market is set to grow to over US$45.0 billion by 2012, driven by the uptake of newer antibacterial agents such as glycopeptides and carbapenems which demonstrate resistance to methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) as well as other emerging strains.
Pharmaceutical companies continue to develop a new generation of antibacterial agents such as cephalosporins, macrolides and quinolones to overcome the major issue of drug resistance but this is not without the struggle and threat of bacterial resistance. By attending SMi’s 10th Annual Superbugs & Superdrugs; A focus on antibacterials conference, you will be able to:
DISCOVER the main antibacterial targets that are worth investing in. LEARN state-of-the-art therapeutic mAbs for bacterial infections. UNDERSTAND pioneering antisense strategies for bacteria. DIVE into the R&D pipeline and inspect the novel advances in drug development. FAMILIARISE yourself with up-to-date regulatory aspects. UPDATES on Phage therapy, quorum sensing, and diagnostics. ASCERTAIN pioneering developments in both gram-positive and gram-negative bacteria. Do not miss this opportunity to find out the incentives for development and learn of the advances in the pipeline for antibacterials. Hear international case studies and expert opinions from leaders in the field, including: - Dr Kenneth Tack, Executive Director, Targanta
- Dr Neil S Ryder, Executive Director, Infectious Diseases, Novartis
Dr Paul Miller, Executive Director, Anti-Bacterials, Pfizer Dr Brian Noonan, Director of Molecular Bioscience, AstraZeneca - Dr Jeff Hermes, Senior Director Microbil Biochemistry, Merck
Dr Monique Twynholm, Director, Anti-Infectives, GlaxoSmithKline - Dr E David G McIntosh, Medical Director Infectious Diseases, Wyeth
- Dr Lloyd Czaplewski, Director of Research, Prolysis
- Prof. Malcolm G. P. Page, Head of Biology, Basilea
- Dr William Weiss, Director, Drug Evaluation, Cumbre Pharmaceuticals
Dr Beatrice Allain, Director, Therapeutic Division, Biophage Pharma Dr Ly Tam Phan, Senior Director Medicinal Chemistry, Enanta Pharmaceuticals Dr Jeff Alder, Vice Presedent, Drug Discovery and Evaluation, Cubist Pharmaceuticals Dr Nafsika Georgopapadakou, Vice President of Research, Novabay Pharmaceuticals Dr Albert Collinson, Chief Business Officer, Rib - X - Pharmaceuticals Dr Nora Kaarela, Chief Executive Officer, IPSAT Therapies Dr Hans-Henrik Kristensen, Senior manager, Novozymes A / S Dr Thomas Henkel, CEO, Intermed Discovery GmBh
Who should attend Superbugs & Superdrugs? You should attend this conference if you are an Executive, Director, Chemist or Scientist working in the pharmaceutical or biotech industries within: - Microbiology
- Immunology
- Infectious Diseases
- Medicinal Chemistry
- Clinical Pharmacology
- Drug Discovery
- New Product Development
- Scientific Affairs
- Licensing
- Antibiotics
- Infection Discovery
- Drug evaluation
- Molecular Biotechnology
- Drug Development
- Project Management
- Preclinical Development
- Portfolio Management
This year's conference is being attended by the following companies: - Novartis
- Novozymes A / S
- AM-Pharma BV
- AstraZeneca
- GlaxoSmithKline
- LEO Pharma
- Wyeth
- Summit plc
- Plant Bioscience (PBL)
- Mutabilis SA
- Intermed Discovery GmBh
- Anacor Pharmaceuticals Inc
- Janssen-Cilag Limited
- Meiji Seika Kaisha
- NOVEXEL
- Rib-X Pharmaceuticals
- Prolysis
- Novabay Pharmaceuticals
| - IPSAT Therapies
- Merck
- Pfizer
- Aquapharm Biodiscovery
- Arpida
- Enanta
- Cubist Pharmaceuticals
- Eurofins Medinet
- University Medical Centre Utrecht
- Targanta Therapeutics
- Cipan - Companhia Industiral Produtora De Antibioticos S A
- Combinature Biopharma A G
- Aquapharm Biodiscovery
- Cumbre Pharmaceuticals
- Basilea
- Biophage Pharma
|
|
Events Home Page
